<div id="readability-page-1"><div><p>CStone Pharmaceuticals announced that the Company will present one of its autoimmune and inflammation pipeline assets, CS2015 (OX40L/TSLP bispecific antibody), in the format of an ePoster plus an on-site oral presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma &amp; Immunology (ACAAI). ACAAI is one of the most influential academic conferences in the fields of allergies, asthma, and immunology, attracting experts and scholars around the world to discuss the latest scientific advancements. This marks the first presentation of CS2015 at an international academic conference.</p><p>The full content of the abstract and eposter is now officially available on the ACAAI website. Key highlights of the presentation: CS2015 features an asymmetric molecular design that simultaneously targets OX40L andTSLP, two clinically validated critical regulators of type 2 inflammation. The molecule incorporates an engineered Fc region with reduced binding affinity for FcgR, which extends its in vivo half-life and optimizes its pharmacokinetic (PK) profile to support long-term dosing intervals.</p><p>CS2015 also exhibits excellent molecular stability, facilitating the development of high-concentration subcutaneous formulations. Its strong developability profile further supports high-yield and scalable manufacturing. Dual Blockade: CS2015 lead molecule demonstrated potent inhibition of OX40L/OX40 and TSLP/TSLPR downstream signaling: CS2015 potently interrupted the engagement of hOX40L on hOX40 reporter cells and hTSLP on hTSLPR/IL-7Ra reporter cells, respectively; The blocking activities of CS2015 were comparable to those of benchmark (parental) antibodies, with single or sub nanomolar IC50s.</p><p>Low viscosity (scored at only 3.7 for a 100 mg/ml solution), promising for subcutaneous injection at high-concentration; Potent efficacy in the intranasal OVA/TSLP-induced asthma model by decreasing the secretion of IL-4, CCL17, IgE, etc., and alleviating pulmonary pathological changes. CStone will further advance the development of CS2015 to treat Th2 cell-mediated inflammation diseases, including AD, asthma, hidradenitis suppurativa (HS), chronic obstructive pulmonary disease (COPD), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), etc. The presentation schedule is as follows: Title: CS2015 a TSLP/OX40L Bispecific Antibody as a Potential Novel Therapeutic Agent for Type 2 Inflammation diseases.</p></div></div>

基石藥業-B

<p>基石藥業將於 2025 年美國過敏、哮喘和免疫學會年會上展示其自身免疫和炎症管線資產 CS2015（OX40L/TSLP 雙特異性抗體）。這是 CS2015 首次在國際學術會議上進行展示。該分子靶向 OX40L 和 TSLP，顯示出對其信號通路的強效抑制以及良好的藥代動力學特性。CS2015 旨在治療各種由 Th2 細胞介導的炎症性疾病。此次展示將強調其作為治療 2 型炎症疾病的新型治療劑的潛力</p>

基石藥業將展示其自身免疫和炎症領域的管線資產之一，CS2015（OX40L/TSLP 雙特異性抗體）